Obstetrik nrdenlerle magnezyum sülfat alan hastaların analizi
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada, obstetrik nedenlerle magnezyum sülfat alan hastaların değerlendirilmesi amaçlanmıştır. Bu amaçla hastaların yaşları, gravida, parite bilgileri, doğum haftaları, magnezyum sülfat alma zamanları gibi değişkenler değerlendirilmiş; ayrıca hemoglobin, platelet, aspartat aminotransferaz ,alanin aminotransferaz , üre, kreatinin gibi değerleri de magnezyum sülfat alma durumu çerçevesinde incelenmiştir. 01.01.2009 – 01.01.2023 tarihleri arasında Trakya Üniversitesi Kadın Doğum Servisi'ne yatırılarak takipleri sırasında preeklampsi, eklampsi nedenleriyle ve nöroprotektif amaçlı magnezyum sülfat kullanılan gebelerin obstetrik ve neonatal sonuçları araştırılmıştır. Araştırmada toplam 535 gebenin verileri incelenmiştir. Nöroprotektif amaçlı tedavi uygulanan gebe sayısı 191 (%35,7), postnatal eklampsi profilaksisi amaçlı tedavi uygulanan gebe sayısı 259 (%48,4) ve antenatal eklampsi tedavisi/profilaksisi uygulanan gebe sayısı 85'tir (%15,9). En yüksek yüzdeye sahip grup postnatal eklampsi profilaksisi/tedavisi ve en düşük yüzdeye sahip grup antenatal eklampsi profilaksisi/tedavisi grubudur. Nöroprotektif amaçlı magnezyum sülfat verilen kadınlarda tedavinin verilme zamanı, doğum zamanı daha erken bulunmuştur. Ayrıca bu gebelerde hemoglobin, üre, kreatinin, sistolik ve diastolik kan basıncı miktarı daha az, platelet miktarı daha yüksektir. Postnatal eklampsi profilaksisi/tedavisi nedeniyle tedavi verilen kadınlarda ise aspartat aminotransferaz miktarı daha yüksek bulunmuştur. Antenatal eklampsi profilaksisi/tedavisi amaçlı magnezyum sülfat verilen kadınlarda 24 saatlik idrar miktarı daha fazla tespit edilmiştir.
This study aims to evaluate patients receiving magnesium sulfate for obstetric reasons. In this context, factor ssuch as patients' ages, gravidity, parity information, gestational weeks, timing of magnesium sulfate administration, as well as values such as hemoglobin, platelet count, aspartate aminotransferase,alanine aminotransferase , urea, and creatinine, were assessed in the context of magnesium sulfate administration. Obstetric and neonatal outcomes of pregnant women admitted to the Trakya University Obstetrics Department for follow-up between January 01, 2009, and January 01, 2023, and who received magnesium sulfate for preeclampsia, eclampsia, preterm labor, and neuroprotective purposes, were investigated. A total of 535 women's data were examined. The number of pregnant women receiving neuroprotective treatment is 191 (35.7%), the number of pregnant women receiving postnatal eclampsia prophylaxis treatment is 259 (48.4%), and the number of pregnant women receiving antenatal eclampsia treatment/prophylaxis is 85 (15.9%). The group with the highest percent age is the postnatal eclampsia prophylaxis group, and the group with the lowest percentage is the antenatal eclampsia treatment/prophylaxis group.In women receiving magnesium sulfate for neuroprotective purposes, the timing of treatment and delivery was found to be earlier. Additionally, in these pregnant women, hemoglobın, urea, creatinine, systolic and diastolic blood pressure levels were lower, and platelet count was higher. Women who received treatment for postnatal eclampsia prophylaxis had higher aspartate aminotransferase levels. In women receiving magnesium sulfate for antenatal eclampsia treatment, a greater amount of urine output was detected over 24 hours.
This study aims to evaluate patients receiving magnesium sulfate for obstetric reasons. In this context, factor ssuch as patients' ages, gravidity, parity information, gestational weeks, timing of magnesium sulfate administration, as well as values such as hemoglobin, platelet count, aspartate aminotransferase,alanine aminotransferase , urea, and creatinine, were assessed in the context of magnesium sulfate administration. Obstetric and neonatal outcomes of pregnant women admitted to the Trakya University Obstetrics Department for follow-up between January 01, 2009, and January 01, 2023, and who received magnesium sulfate for preeclampsia, eclampsia, preterm labor, and neuroprotective purposes, were investigated. A total of 535 women's data were examined. The number of pregnant women receiving neuroprotective treatment is 191 (35.7%), the number of pregnant women receiving postnatal eclampsia prophylaxis treatment is 259 (48.4%), and the number of pregnant women receiving antenatal eclampsia treatment/prophylaxis is 85 (15.9%). The group with the highest percent age is the postnatal eclampsia prophylaxis group, and the group with the lowest percentage is the antenatal eclampsia treatment/prophylaxis group.In women receiving magnesium sulfate for neuroprotective purposes, the timing of treatment and delivery was found to be earlier. Additionally, in these pregnant women, hemoglobın, urea, creatinine, systolic and diastolic blood pressure levels were lower, and platelet count was higher. Women who received treatment for postnatal eclampsia prophylaxis had higher aspartate aminotransferase levels. In women receiving magnesium sulfate for antenatal eclampsia treatment, a greater amount of urine output was detected over 24 hours.
Açıklama
Tıpta Uzmanlık
Anahtar Kelimeler
Kadın Hastalıkları ve Doğum, Obstetrics and Gynecology
